Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Wnt-Pathway Driven Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TNKS/TNKS-1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNKS-1 Catalytic Domain / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View TNKS Products |
| Gene Delivery | TNKS Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View TNKS Products |
| Benchmark Ab | Anti-TNKS Reference Antibody Recombinant positive control for western blot and IP. |
View TNKS Products |
| Validator | TNKS siRNA Set For knockdown verification and pathway signaling baseline establishment. |
View TNKS Products |
| Related Target A | TNKS2 Crucial homolog (PARP5B) for dual-inhibitor screening or selectivity profiling. |
View TNKS2 Products |
| Related Target B | PARP1 Core PARP family member for strict off-target counter-screening. |
View PARP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pan-PARP Off-Target Toxicity | High-purity homologous PARP proteins strictly verified by mass spec and activity assays. |
| Enzymatic Assay Reproducibility | Lot-to-lot consistency with standardized specific activity and Native Glycosylation/Folding. |
| Lack of Reliable Cellular Controls | Sequence-verified stable cell line tools (Lentivirus) for robust cell-based reporter assays. |
| False Positives in Screening | Validated siRNA included for target-specificity checks. |
Live TNKS/TNKS-1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TNKS/TNKS-1 (Tankyrase 1) therapeutics is evolving, with major players refining small molecule inhibitors to target the Wnt/β-catenin pathway. As first-generation therapies experienced dose-limiting on-target intestinal toxicities, the next wave of R&D is targeting highly selective inhibitors, PROTAC-mediated degradation, and strategic combination therapies to widen the therapeutic window for colorectal cancer and fibrotic indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Novartis, Eisai | Colorectal Cancer (APC mut) | Selectivity Assay (Need High-Purity PARP panels) |
| PROTAC Degrader | Emerging Biotechs | Solid Tumors | Ternary Complex Validation (Need pure TNKS protein) |
| Combination Therapy | Academic / Pharma | Refractory Cancers | Pathway Reporter Assays (Need siRNA/Lentivirus) |